BioGaia AB (publ) (BIOG-B.ST)

SEK 110.5

(0.82%)

Market Cap (In SEK)

10.76 Billion

Revenue (In SEK)

1.29 Billion

Net Income (In SEK)

365.35 Million

Avg. Volume

86.93 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
94.75-136.6
PE
-
EPS
-
Beta Value
0.593
ISIN
SE0017769995
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Theresa P. Agnew
Employee Count
-
Website
https://www.biogaia.com
Ipo Date
2000-01-03
Details
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylori–the gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.